Arcturus Therapeutics (ARCT) Misses Q4 EPS by 92c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($1.11), $0.92 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.77 million versus the consensus estimate of $63.22 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral